Saturday 17 October 2026 Export SNGX’s income statement to Excel — free account

Soligenix Inc.

Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023. In the quarter to June 2026, EPS grew 85.4% and free cash flow grew 37.8%, each against the same quarter a year earlier.

0.35 0.01 −2.78%

Follow SNGX

Alert me

Market cap: $7.7M
P/E: 0.0×
Fwd P/E: −0.5×
Dividend yield: —
F-score: n/a
Altman Z: −38.90
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 7.73

Revenue 0.49

Net Income (10.24)

Free Cash Flow (9.74)

Net Debt (9.81)

Current Ratio 2.77

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.53)

P/S ratio 11.29

P/B ratio 0.84

Past 5Y EPS Growth —

This Y EPS Growth 81.31%

Next Y EPS Growth 37.50%

Next Y revenue growth 318.76%

Next 5Y EPS Growth 48.16%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 60.27%

10-year low 10-year high

P/B against its own 10 years 3.85%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	8	8	8	10
Receivables	0	—	—	—
Inventory	—	—	—	—
Other	—	0	0	0
	10	9	9	10

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	2	1	—	—
Other	—	—	—	—
	6	5	4	4

Compound Annual Growth %

	10y	5y	3y
Sales	(33.48%)	(51.88%)	(47.48%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	7.18%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	0	0	—	—	0
’23	0	0	0	0	1
’22	0	0	0	0	1
’21	0	0	0	0	1
’20	1	1	1	0	2
’19	1	2	1	1	5

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(2)	(3)	(3)	(3)	(10)
’24	(1)	(2)	(3)	(2)	(8)
’23	(2)	(2)	(3)	(2)	(9)
’22	(3)	(3)	(3)	(4)	(13)
’21	(4)	(2)	(3)	(3)	(12)
’20	(3)	(2)	(3)	(4)	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(2)	(3)	(3)	(3)	(10)
’24	(1)	(2)	(3)	(2)	(8)
’23	(2)	(2)	(3)	(2)	(9)
’22	(3)	(3)	(3)	(4)	(13)
’21	(4)	(2)	(3)	(3)	(12)
’20	(3)	(2)	(3)	(4)	(11)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.28)	(0.12)	—	—	—
’25	(1.06)	(0.82)	(0.58)	0.24	(2.14)
’24	(2.88)	(1.31)	(0.78)	(1.14)	(4.98)
’23	(5.76)	(3.52)	(2.56)	(2.56)	(12.64)
’22	(23.99)	(14.39)	(19.19)	(20.82)	(76.96)
’21	(14.39)	(11.99)	(21.59)	(26.39)	(74.36)
’20	(76.76)	(23.99)	(14.39)	(45.58)	(153.52)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	492.00	417.60	192.00	156.00	290.40	158.40	91.20	6.08	1.83	1.09	Analyst estimates 2026–2028 Powerpack
	High	3,000.00	1,219.20	888.00	357.60	849.60	595.20	240.00	129.60	19.20	6.23
People
People	Employees	19	18	14	16	18	15	15	15	16	14
	Revenue/emp, $m	0.55	0.30	0.37	0.29	0.13	0.05	0.06	0.06	0.01	0.00
Income, $m
Income, $m	Revenue	10	5	5	5	2	1	1	1	0	—
	Gross margin, %	19.29	20.66	12.28	22.95	22.82	11.60	41.95	11.59	0.00	—
	EBT	(4)	(8)	(9)	(10)	(19)	(13)	(15)	(8)	(9)	(12)
	EBT margin, %	(36.13)	(139.23)	(169.80)	(215.26)	(785.17)	(1,627.53)	(1,575.86)	(942.16)	(7,266.08)	0.00
	Net income	(3)	(7)	(9)	(9)	(18)	(13)	(14)	(6)	(8)	(11)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	720.61	212.21	95.47	57.30	20.59	4.93	5.29	1.73	0.07	0.00
	Earnings	(223.09)	(246.96)	(163.12)	(115.14)	(153.52)	(74.36)	(76.96)	(12.64)	(4.98)	(2.14)
	Cash flow	(343.61)	(254.32)	(131.96)	(92.94)	(99.95)	(70.21)	(70.51)	(17.74)	(5.06)	(1.98)
	Capex	(0.50)	(1.03)	(0.02)	(0.31)	(0.06)	(0.07)	(0.07)	0.00	0.00	0.00
	Free cash flow	(344.11)	(255.35)	(131.98)	(93.25)	(100.01)	(70.28)	(70.58)	(17.74)	(5.06)	(1.98)
	Book value	510.15	246.86	114.39	18.03	32.65	64.13	(13.77)	5.20	2.48	1.02
	Shares, m	0	0	0	0	0	0	0	0	2	5
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	P/S	0.79	2.53	2.16	6.07	14.92	32.13	21.78	7.86	9.06	—
	P/B	1.12	2.18	1.80	19.30	9.41	2.47	0.00	2.62	1.09	—
	EV/Sales	(0.05)	1.10	0.45	4.93	11.36	12.62	18.38	1.68	(1.93)	—
	EV/FCF	0.11	(0.91)	(0.32)	(3.03)	(2.34)	(0.89)	(1.38)	(0.16)	0.11	—
Cash, $m
Cash, $m	Operating cash flow	(5)	(7)	(7)	(8)	(11)	(12)	(13)	(9)	(8)	(10)
	Capex	0	0	0	0	0	0	0	—	—	0
	Free cash flow	(5)	(7)	(7)	(8)	(11)	(12)	(13)	(9)	(8)	(10)
Balance, $m
Balance, $m	Working capital	7	6	6	1	13	20	(3)	3	4	5
	Total debt	—	—	—	0	10	10	10	3	1	—
	Net debt	(9)	(8)	(9)	(5)	(8)	(16)	(3)	(5)	(6)	(8)
	Shareholders’ equity	7	6	6	1	4	11	(2)	3	4	5
Returns, %
Returns, %	ROA	(36.77)	(72.13)	(88.82)	(102.43)	(127.87)	(53.68)	(67.06)	(51.01)	(88.11)	(121.75)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(87.96)	(104.21)	(141.27)	(241.83)	(680.47)	(173.54)	(334.43)	(23,801.16)	(248.98)	(235.50)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Jun 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR	$8.1M	— (loss-making)	—	—	n/m	−510.28% (below 0%: shrinking)	0.00%	0.00%	Compare
XTLB XTL Biopharmaceuticals Ltd.	$8.1M	— (loss-making)	—	−39.32% (below 0%: shrinking)	n/m	+46.78% (above 0%: growing)	0.00%	0.00%	Compare
KPTI Karyopharm Therapeutics Inc.	$8.0M	— (loss-making)	— (loss-making)	−11.86% (below 0%: shrinking)	n/m	−33.34% (below 0%: shrinking)	96.75%	(67.38%)	Compare
CNSP CNS Pharmaceuticals, Inc.	$7.9M	— (loss-making)	—	—	n/m	+33.70% (above 0%: growing)	0.00%	0.00%	Compare
APRE Aprea Therapeutics, Inc.	$7.8M	— (loss-making)	— (loss-making)	−98.40% (below 0%: shrinking)	n/m	−5.22% (below 0%: shrinking)	100.00%	0.00%	Compare
SNGX Soligenix Inc.	$7.7M	— (loss-making)	— (loss-making)	−98.89% (below 0%: shrinking)	n/m	+37.83% (above 0%: growing)	0.00%	0.00%
CURX Curanex Pharmaceuticals Inc	$7.6M	— (loss-making)	—	—	n/m	−272.32% (below 0%: shrinking)	—	0.00%	Compare
MBRX Moleculin Biotech, Inc.	$7.6M	0.0×	—	—	n/m	−19.26% (below 0%: shrinking)	0.00%	0.00%	Compare
CALC CalciMedica Inc.	$7.4M	— (loss-making)	—	—	n/m	+31.42% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$7.8M	—	—	−39.32%	—	−12.24%	0.00%	0.00%

All 614 Biotechnology stocks →

Soligenix Inc. (SNGX) key facts

Concern: Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023.
Soligenix Inc. (SNGX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SNGX traded at $0.35, a market capitalization of $7.7 million.
Return on equity was −235.5% and debt-to-equity 0.00.
Its Altman Z-score is −38.90 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.